Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Gets FDA Emergency Use Authorization for Pooled Sample SARS-CoV-2 Test Kit

NEW YORK — The US Food and Drug Administration last week granted Emergency Use Authorization for Thermo Fisher Scientific's TaqPath COVID-19 Pooling Kit.

The kit is designed to detect the ORF1ab, N, and S genes of SARS-CoV-2 in pooled samples containing up to five individual nasopharyngeal, oropharyngeal, anterior nasal, or mid-turbinate nasal swab specimens collected by healthcare providers. It runs on Thermo Fisher's Applied Biosystems QuantStudio 7 RT-PCR instrument and may be used by any lab that is CLIA-certified to perform high-complexity tests.

In April, Thermo Fisher received EUA from the FDA for a high-throughput, automated SARS-CoV-2 test kit, which is based on the Waltham, Massachusetts-based company's previously authorized Applied Biosystems TaqPath COVID-19 Combo Kit.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.